Including Ortiz et al. [8] (ALDH1 at the invasive tumor front) as a 1-year hazard ratio in an exploratory sensitivity analysis markedly increased heterogeneity (pooled HR 0.77, 95% CI 0.16–3.81; I2 73.7%), supporting its exclusion from the primary IHC meta-analysis due to the different time horizon. The gene discussed is ALDH1A1; the disease is neoplasm.